Introduction to Apomorphine

• USP drug

• Used as a pharmacologic agent since 1869

  • Over 1,100 literature citations
  • Therapeutic doses ranged from 0.2 to 1500 mg
  • Approximately 8,000 patients/subjects treated in clinical trials

• Approved in 12 countries for multiple indications, including Parkinson’s Disease

  • Daily administration
  • Usual dose 3 to 30 mg, subcutaneously

• Dopaminergic properties recognized in 1967

• Central erectogenic effect recognized in the late 1970’s

• Activates DA receptors in hypothalamic and limbic neural pathways

Introduction-Uprima

Previous slide

Next slide

Back to first slide

View graphic version